by Medicine by Design | Apr 15, 2024
CCRM, the publisher of Signals, has enhanced its long-standing relationship with the University of Toronto’s Medicine by Design through a new strategic alliance. This profile is one in a series of profiles that feature “people of Medicine by Design.” Some minor edits...
by Cal Strode | Mar 29, 2023
Few people have made bigger contributions to the Canadian regenerative medicine ecosystem than Dr. Peter Zandstra. He is co-founder of two companies advancing cutting-edge biotechnologies for therapeutic use (Notch Therapeutics and ExCellThera, both of which are...
by Cal Strode | Sep 15, 2022
OmniaBio Inc., a subsidiary of CCRM, is building the largest facility of its kind in Canada, providing specialized manufacturing to the flourishing cell and gene therapy (CGT) industry. The new contract development and manufacturing organization (CDMO) will focus on...
by Cal Strode | May 18, 2022
To mark Signals’ 10-year anniversary, we caught up with some of our active current bloggers — Lyla El-Fayomi, David Kent and Sara Nolte — to get to know them a little better, talk science communication and, in next week’s follow-up post, predict what a science-enabled...
by Hamideh Emrani | Apr 4, 2017
The month of March is a time for celebrating women around the world. As a science enthusiast, I have been so inspired by the women I see succeeding in the research field. Since I started writing for this blog, I have had the chance to write about and interview female...
by Stacey Johnson | Aug 12, 2016
Andrew Pelling is a self-described biohacker (and also the Canada research chair in experimental cell mechanics at the University of Ottawa) who makes ears out of apples and sees inspiration all around him – but science fiction (The Matrix, Little Shop of Horrors) is...
Comments